Beta-Blockers
Key Points
- Beta-blockers (beta-adrenergic blockers) block beta-1 and/or beta-2 receptors, decreasing heart rate, myocardial contractility, and blood pressure.
- Cardioselective beta-1 blockers (metoprolol, atenolol) primarily affect the heart; nonselective (propranolol, carvedilol) also affect lungs and peripheral vasculature.
- Hold dose and notify provider if heart rate <60 beats/minute or blood pressure is critically low before administration.
- Abrupt discontinuation is dangerous — always taper over 1–2 weeks to prevent rebound tachycardia, angina, or MI.
- Key hazard: mask hypoglycemia symptoms in diabetic patients — monitor blood glucose carefully.
Mechanism of Action
Beta-blockers competitively inhibit catecholamines (epinephrine, norepinephrine) at adrenergic receptor sites:
| Receptor | Location | Effect of Blockade |
|---|---|---|
| Beta-1 | Heart, kidneys | ↓ Heart rate, ↓ myocardial contractility, ↓ renin release → ↓ blood pressure |
| Beta-2 | Lungs, peripheral vasculature | Bronchoconstriction, peripheral vasoconstriction (nonselective agents) |
Cardioselective agents (metoprolol, atenolol) primarily block beta-1 receptors — safer in pulmonary disease but bronchoconstriction still possible at higher doses.
Common Beta-Blockers
| Drug | Selectivity | Routes | Common Indication |
|---|---|---|---|
| Metoprolol tartrate (Lopressor) | Beta-1 selective | PO, IV | Hypertension, MI, heart failure; IV pathways may use 5 mg slow push over 1-2 minutes and repeat dosing per protocol/order |
| Metoprolol succinate (Toprol-XL) | Beta-1 selective | PO (extended-release) | Heart failure, hypertension |
| Atenolol (Tenormin) | Beta-1 selective | PO | Hypertension, angina |
| Carvedilol (Coreg) | Nonselective + alpha | PO | Heart failure, hypertension |
| Propranolol (Inderal) | Nonselective | PO, IV | Dysrhythmias, migraine, anxiety, hypertension |
| Labetalol | Nonselective + alpha | PO, IV | Hypertensive emergencies, pregnancy-related hypertension |
Indications
- Hypertension (first-line or adjunct)
- Heart failure (carvedilol, metoprolol succinate — reduce mortality)
- Angina and coronary artery disease
- Dysrhythmias: rate control in atrial fibrillation, supraventricular tachycardia
- Acute myocardial infarction — reduce cardiac workload and infarct size
- Migraine prophylaxis, essential tremor (propranolol), anxiety (off-label)
Nursing Assessment
NCLEX Focus
Always assess apical heart rate AND blood pressure before administering any beta-blocker. Hold if HR <60 bpm or if significant hypotension is present — contact provider with assessment findings before giving the dose.
Pre-administration:
- Obtain apical heart rate and blood pressure — hold if HR <60 bpm or per facility protocol
- Assess for contraindications: active bronchospasm, decompensated heart failure, severe bradycardia, AV block
- Review diabetes status — beta-blockers mask sympathetic signs of hypoglycemia (tachycardia, tremor)
- For IV metoprolol, anticipate rapid onset (about 5 minutes), peak effect around 15-30 minutes, and duration near 3-6 hours; plan near-term reassessment windows accordingly.
Contraindications:
- Moderate to severe asthma or COPD (especially nonselective agents — bronchoconstriction risk)
- Bradycardia (HR <60 bpm), second or third-degree AV block
- Cardiogenic shock, decompensated acute heart failure
- Sick sinus syndrome without pacemaker
Nursing Interventions
- Administer extended-release formulations intact — do not crush or split (Toprol-XL, Coreg CR)
- Monitor blood pressure and heart rate regularly; educate client on self-monitoring technique
- Monitor blood glucose in diabetic clients — adrenergic signs of hypoglycemia are blunted
- During IV administration, monitor heart rate, blood pressure, and ECG rhythm closely for bradycardia, hypotension, or conduction worsening.
Adverse effects to monitor:
- Bradycardia and hypotension — most serious cardiovascular adverse effects
- Fatigue, dizziness, orthostatic hypotension
- Bronchoconstriction (especially nonselective agents — monitor breath sounds)
- Cold extremities (peripheral vasoconstriction)
- Depression, insomnia, nightmares (CNS effects)
- Masking of hypoglycemia symptoms in diabetes
Abrupt Discontinuation Risk
Beta-blockers must never be stopped abruptly. Rebound hypertension, unstable angina, or acute MI can result. Taper the dose over 1–2 weeks under provider supervision when discontinuing therapy.
Patient education:
- Take at the same time each day; never skip or suddenly stop taking
- Report dizziness, severe fatigue, or shortness of breath to provider
- Use caution with position changes — orthostatic hypotension
- Avoid caffeine and alcohol (increase cardiovascular stress)
- Diabetic clients: monitor blood glucose more frequently; rely on glucose readings rather than symptoms to detect hypoglycemia
- Inform dentists and other providers of beta-blocker use before procedures
Related Concepts
- cardiovascular-system — Heart rate and contractility regulation affected by beta-receptor blockade.
- hypertension-assessment-and-management — Beta-blockers as first-line or adjunct antihypertensive agents.
- heart-failure — Carvedilol and metoprolol succinate as evidence-based heart failure therapies.
- systematic-ecg-interpretation-and-dysrhythmia-triage — Beta-blockers for rate control in atrial fibrillation and supraventricular tachycardia.
- diabetes-mellitus — Risk of masked hypoglycemia symptoms in diabetic patients on beta-blockers.
- high-alert-medications — Beta-blockers as medications requiring pre-dose vital sign assessment.
Self-Check
- A client with hypertension and type 2 diabetes is started on metoprolol. What specific monitoring is required, and why?
- Before administering metoprolol 25 mg PO, the nurse assesses an apical heart rate of 54 bpm. What is the appropriate nursing action?
- A client asks why they cannot stop taking their beta-blocker suddenly. What is the evidence-based explanation?